Azacitidine

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Myelodysplastic Syndromes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also in development:Acute Myeloid Leukemia · Phase 3

Also approved (2)
US
  • Juvenile Myelomonocytic Leukemia (JMML) VIDAZA is indicated for the treatment of pediatric patients aged one month and older with newly diagnosed JMML.
Product first approved 2004Outside this platform's coverageFDA label
EU
  • Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification. Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not...
Product first approved 2008EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (45)
Acute Myeloid Leukemia
NCT07007312 · Kura Oncology, Inc.
2025-09-26 – 2031-11 · Acute Myeloid Leukemia (AML)
What this study did
NCT05183035 · PedAL BCU, LLC
2022-10-01 – 2031-04 · Acute Myeloid Leukemia
What this study did
NCT07407140 · Institute of Hematology & Blood Diseases Hospital, China
2026-04-30 – 2030-12-31 · AML, Adult
What this study did
NCT07686965 · Institute of Hematology & Blood Diseases Hospital, China
2026-08-10 – 2030-08-10 · Acute Myeloid Leukemia (AML), Maintenance Treatment, Hematopoetic Stem Cell Transplantation
What this study did
NCT07925190 · Beijing InnoCare Pharma Tech Co., Ltd.
2026-11-03 – 2030-06 · Acute Myeloblastic Leukemia
What this study did
NCT07478991 · PETHEMA Foundation
2026-07-02 – 2030-04 · Acute Myeloid Leukemia, Adult
What this study did
NCT07407660 · Peking University People's Hospital
2026-02-01 – 2030-02-01 · Acute Myeloid Leukemia
What this study did
NCT07469046 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-04-10 – 2029-03-31 · Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)
What this study did
NCT06345365 · Zhongnan Hospital
2024-01-18 – 2028-12-31 · Acute Myeloid Leukaemia
What this study did
NCT07132684 · Institute of Hematology & Blood Diseases Hospital, China
2025-08-31 – 2028-08-30 · AML, Adult
What this study did
NCT07486479 · The First Affiliated Hospital of Soochow University
2026-03-10 – 2027-12-31 · Acute Myeloid Leukemia (AML)
What this study did
NCT07514936 · Chinese PLA General Hospital
2024-11-18 – 2027-12-31 · Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
What this study did
NCT05264883 · The First Affiliated Hospital with Nanjing Medical University
2021-03-01 – 2025-02-28 · Acute Myeloid Leukemia
What this study did
NCT03765541 · University Hospital, Toulouse
2020-01-13 – 2024-05-31 · Relapsed or Refractory Acute Myeloid Leukemia
What this study did
NCT04722952 · The First Affiliated Hospital of Soochow University
2021-05-01 – 2024-01-01 · Immunotherapy, Refractory Leukemia, Relapsed Adult AML, Acute Myeloid Leukemia
What this study did
NCT05457361 · Nanfang Hospital, Southern Medical University
2022-03-01 – 2023-12-31 · Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine
What this study did
NCT04490707 · Ge Zheng
2020-09-01 – 2022-12-30 · Acute Myeloid Leukemia in Remission
What this study did
NCT04842604 · Pfizer
2021-05-17 – 2022-12-02 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
What this study did
NCT05188326 · Associazione Qol-one
2010-11-28 – 2021-09-27 · Acute Myeloid Leukemia
What this study did
NCT02319135 · PETHEMA Foundation
2014-10 – 2019-10-28 · Acute Myeloid Leukemia
What this study did
NCT01074047 · Celgene
2010-06-01 – 2016-07-25 · Acute Myeloid Leukemia
What this study did
NCT01067274 · Acute Leukemia French Association
2010-04 – 2016-04 · Acute Myeloid Leukemia
What this study did
NCT00422890 · Technische Universität Dresden
2007-01 – 2009-12 · Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
Myelodysplastic Syndromes
NCT06465953 · Institut de Recherches Internationales Servier
2024-12-03 – 2028-12-01 · Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
What this study did
NCT05883956 · Otsuka Australia Pharmaceutical Pty Ltd
2023-12-20 – 2025-05 · Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference
What this study did
NCT03268954 · Takeda
2017-11-28 – 2024-10-14 · Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
What this study did
NCT04266301 · Novartis Pharmaceuticals
2020-06-08 – 2024-10-02 · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
What this study did
NCT03978364 · Shandong Provincial Hospital
2019-06-01 – 2022-12-31 · Myelodysplastic Syndromes,Acute Myeloid Leukemia
What this study did
NCT03745716 · Aprea Therapeutics
2019-01-11 – 2022-01-14 · MDS
What this study did
NCT01928537 · Traws Pharma, Inc.
2013-08 – 2017-06-29 · Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
What this study did
NCT01186939 · Celgene
2007-04-01 – 2009-09-01 · Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT05678933 · Tianjin Medical University Cancer Institute and Hospital
2023-01-01 – 2029-12-01 · Peripheral T-cell Lymphoma Targeted Therapy
What this study did
NCT04184505 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2020-11-27 – 2026-03-01 · High-risk MDS
What this study did
NCT05075460 · Peking Union Medical College Hospital
2021-10-01 – 2024-10-30 · T-cell Lymphoma
What this study did
NCT02981615 · Sheba Medical Center
2017-08-01 – 2022-07-30 · Prevention
What this study did
Phase 2/3 (14)
Acute Myeloid Leukemia
NCT03013998 · Beat AML, LLC
2016-11 – 2032-12 · Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
What this study did
NCT07425808 · European Organisation for Research and Treatment of Cancer - EORTC
2026-12-01 – 2032-02-01 · AML (Acute Myeloid Leukemia)
What this study did
NCT05404906 · The First Affiliated Hospital of Soochow University
2022-06-25 – 2030-06 · Acute Myeloid Leukemia (AML) in Remission
What this study did
NCT07651163 · First Affiliated Hospital of Zhejiang University
2026-03-01 – 2029-12 · Acute Myeloid Leukemia (AML), Lisaftoclax
What this study did
NCT07651176 · First Affiliated Hospital of Zhejiang University
2026-03-01 – 2029-12 · Acute Myeloid Leukemia, Lisaftoclax
What this study did
NCT07255872 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-04-02 – 2027-12 · Acute Myeloid Leukemia
What this study did
NCT03092674 · National Cancer Institute (NCI)
2018-02-02 – 2024-06-26 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
What this study did
NCT05175508 · The First Affiliated Hospital of Soochow University
2021-05-01 – 2023-05-01 · AML, MDS, Old Age; Debility, Hematologic Cancer
What this study did
Myelodysplastic Syndromes
NCT07932873 · The Affiliated People's Hospital of Ningbo University
2028-09-01 – 2028-12-01 · MDS (Myelodysplastic Syndrome)
What this study did
NCT04256317 · Taiho Oncology, Inc.
2020-05-21 – 2028-11-01 · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
What this study did
NCT00454480 · The University of New South Wales
2006-08 – 2012-08 · Leukemia, Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT07389616 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-02-01 – 2029-08-01 · Peripheral T Cell Lymphoma
What this study did
NCT04216355 · Fujian Medical University
2020-01 – 2023-12 · MDS-EB
What this study did
Phase 2 (277)
Acute Myeloid Leukemia
NCT05955261 · St. Jude Children's Research Hospital
2023-07-25 – 2034-03 · Acute Myeloid Leukemia
What this study did
NCT07664839 · Shen yang
2026-07-01 – 2032-05-31 · Acute Myeloid Leukemia, NPM1 Mutation, IDH1 Mutation, IDH2 Mutation
What this study did
NCT05442216 · Joshua Zeidner
2024-05-01 – 2031-07-21 · Acute Myeloid Leukemia
What this study did
NCT07078591 · Beijing 302 Hospital
2025-06-20 – 2031-06 · Acute Myeloid Leukemia
What this study did
NCT05554419 · National Cancer Institute (NCI)
2027-01-04 – 2030-12-31 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
What this study did
NCT05904106 · Technische Universität Dresden
2024-04-07 – 2030-09 · Acute Myeloid Leukemia
What this study did
NCT06598384 · Navy General Hospital, Beijing
2024-09 – 2030-09 · Acute Myeloid Leukemia
What this study did
NCT07949370 · Dana-Farber Cancer Institute
2027-03-06 – 2030-07-31 · Relapsed or Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT07672262 · The First Affiliated Hospital of Soochow University
2026-06-01 – 2030-06-01 · Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy
What this study did
NCT07755202 · Florian Kuchenbauer
2026-09-01 – 2030-05-01 · Acute Myeloid Leukemia, AML With FLT3 Mutation
What this study did
NCT06696183 · Technische Universität Dresden
2025-04-25 – 2030-04 · AML - Acute Myeloid Leukemia
What this study did
NCT06456463 · Stemline Therapeutics, Inc.
2025-01-14 – 2030-02-11 · Acute Myeloid Leukemia
What this study did
NCT07060001 · The Methodist Hospital Research Institute
2026-04-09 – 2029-12 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
What this study did
NCT07754799 · Institute of Hematology & Blood Diseases Hospital, China
2026-09-30 – 2029-09-30 · Acute Myeloid Leukemia (AML)
What this study did
NCT07471841 · Timothy Pardee
2026-11 – 2029-06 · IDH1 Mutation, Relapsed / Refractory AML
What this study did
NCT05564390 · National Cancer Institute (NCI)
2024-06-18 – 2029-05-15 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
What this study did
NCT06317649 · National Cancer Institute (NCI)
2024-09-27 – 2029-05-15 · Acute Myeloid Leukemia
What this study did
NCT06782542 · Justin Watts, MD
2026-03-31 – 2029-03-31 · Acute Myeloid Leukemia, IDH1 Mutation
What this study did
NCT07507825 · First People's Hospital of Hangzhou
2026-03-31 – 2029-03-31 · Acute Myeloid Leukemia (AML)
What this study did
NCT06379360 · The First Affiliated Hospital of Soochow University
2019-07-01 – 2028-12-31 · Acute Myeloid Leukemia
What this study did
NCT07514832 · Beijing 302 Hospital
2026-04-15 – 2028-12-31 · AML (Acute Myeloid Leukemia)
What this study did
NCT07548710 · Ruijin Hospital
2026-05-01 – 2028-12-21 · Acute Myeloid Leukemia
What this study did
NCT06014489 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-01-17 – 2028-12 · AML, Adult
What this study did
NCT06470841 · Navy General Hospital, Beijing
2024-09-20 – 2028-12 · Acute Myeloid Leukemia
What this study did
NCT06557421 · Institut Paoli-Calmettes
2026-02-04 – 2028-11-01 · Acute Myeloid Leukemia
What this study did
NCT06635681 · Institute of Hematology & Blood Diseases Hospital, China
2024-09-29 – 2028-10-01 · AML (Acute Myelogenous Leukemia)
What this study did
NCT07813390 · Guangdong Second Provincial General Hospital
2026-09-01 – 2028-08-31 · Acute Myeloid Leukemia (AML)
What this study did
NCT06532552 · The First Affiliated Hospital of Soochow University
2024-07-29 – 2028-08-01 · Acute Myeloid Leukemia, Adult, Newly Diagnosed
What this study did
NCT06511882 · H. Lee Moffitt Cancer Center and Research Institute
2024-11-07 – 2028-08 · Acute Myeloid Leukemia
What this study did
NCT06483906 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2024-07-02 – 2028-07-01 · Acute Myeloid Leukemia
What this study did
NCT06668558 · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
2024-12-16 – 2028-07 · Acute Myeloid Leukemia
What this study did
NCT07605949 · UNC Lineberger Comprehensive Cancer Center
2026-12 – 2028-07 · Leukemia Acute Myeloid
What this study did
NCT06497062 · Shanghai Jiao Tong University School of Medicine
2024-10-30 – 2028-06-30 · Acute Myeloid Leukemia
What this study did
NCT06744556 · Institute of Hematology & Blood Diseases Hospital, China
2025-01-21 – 2028-06-01 · AML
What this study did
NCT07642453 · Hematology department of the 920th hospital
2026-06-01 – 2028-06-01 · Acute Myeloid Leukemia (AML)
What this study did
NCT06504459 · OHSU Knight Cancer Institute
2025-01-03 – 2028-05-01 · Acute Monocytic Leukemia, Acute Myeloid Leukemia
What this study did
NCT03850418 · Henry Ford Health System
2019-07-01 – 2028-02-20 · Myeloid Malignancy
What this study did
NCT07163793 · Northwell Health
2025-08-26 – 2028-02 · Acute Myeloid Leukemia in Remission
What this study did
NCT04801797 · Massachusetts General Hospital
2021-05-20 – 2028-01-01 · Acute Myeloid Leukemia
What this study did
NCT07392242 · Memorial Sloan Kettering Cancer Center
2026-01-27 – 2028-01 · Acute Myeloid Leukemia
What this study did
NCT06429098 · The First Affiliated Hospital of Soochow University
2024-01-01 – 2027-12-31 · Acute Myeloid Leukemia
What this study did
NCT07748455 · Pakistan Blood and Marrow Transplant (PBMT) Group
2026-08-01 – 2027-12-31 · AML, AML (Acute Myeloid Leukemia)
What this study did
NCT07743112 · Maxinovel Pty., Ltd.
2025-09-05 – 2027-12-01 · Acute Myeloid Leukemia
What this study did
NCT06783790 · Institute of Hematology & Blood Diseases Hospital, China
2025-01-20 – 2027-12 · AML (Acute Myelogenous Leukemia)
What this study did
NCT04284787 · National Cancer Institute (NCI)
2021-02-16 – 2027-10-09 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
What this study did
NCT06022003 · French Innovative Leukemia Organisation
2024-01-13 – 2027-10 · AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD
What this study did
Phase 1/2 (144)
Acute Myeloid Leukemia
NCT07508982 · M.D. Anderson Cancer Center
2026-05-22 – 2031-12-12 · AML
What this study did
NCT07770698 · BeOne Medicines
2026-12 – 2031-09 · Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL, Relapsed, Pediatric ALL, Pediatric ALL, B Cell, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric AML, R/R AML, R/R B-cell ALL
What this study did
NCT07148180 · Jacqueline Garcia, MD
2026-02-02 – 2030-12-31 · Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
What this study did
NCT07646821 · M.D. Anderson Cancer Center
2026-10-27 – 2030-12-11 · Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
What this study did
NCT06548230 · M.D. Anderson Cancer Center
2025-03-05 – 2029-12-01 · Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
What this study did
NCT04501120 · Ascentage Pharma Group Inc.
2020-09-28 – 2029-09 · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
What this study did
NCT06611839 · Institute of Hematology & Blood Diseases Hospital, China
2025-10-17 – 2028-10-01 · AML, IDH1 Mutation, Treatment
What this study did
NCT07486726 · Shanghai Jiao Tong University School of Medicine
2026-03-15 – 2028-10 · Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT04140487 · M.D. Anderson Cancer Center
2019-12-17 – 2028-09-01 · Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm
What this study did
NCT05520567 · Astellas Pharma Global Development, Inc.
2023-01-31 – 2028-07-31 · Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
What this study did
NCT07779031 · Liping Dou
2025-05-01 – 2028-05-01 · Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)
What this study did
NCT04588922 · Sellas Life Sciences Group
2021-05-10 – 2027-12-31 · Hematologic Malignancies
What this study did
NCT05270200 · Zhujiang Hospital
2022-02-01 – 2027-12-31 · Leukemia, Myeloid, Acute
What this study did
NCT03471260 · M.D. Anderson Cancer Center
2018-03-19 – 2027-09-30 · Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT05226455 · Groupe Francophone des Myelodysplasies
2022-11-23 – 2027-09-01 · MDS, AML
What this study did
NCT07761533 · Chaser Therapeutics, Inc.
2025-09-08 – 2027-09 · Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
What this study did
NCT06561880 · Institute of Hematology & Blood Diseases Hospital, China
2024-10-08 – 2027-08-31 · FLT3 Gene Mutation, AML
What this study did
NCT03850574 · Aptose Biosciences Inc.
2019-03-11 – 2027-04 · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
What this study did
NCT04068597 · CellCentric Ltd.
2019-08-09 – 2027-03-31 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
What this study did
NCT04086264 · AbbVie
2019-11-06 – 2027-02 · Acute Myeloid Leukemia
What this study did
NCT03862157 · M.D. Anderson Cancer Center
2019-02-27 – 2027-01-31 · Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Overt Primary Myelofibrosis, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Prefibrotic/Early Primary Myelofibrosis
What this study did
NCT04742101 · Institut de Recherches Internationales Servier
2021-03-10 – 2026-03-27 · Acute Myeloid Leukemia
What this study did
NCT04980885 · Akeso
2021-08-13 – 2025-12 · Acute Myeloid Leukemia
What this study did
NCT06508489 · Sanofi
2024-08-13 – 2025-08-08 · Acute Myeloid Leukemia
What this study did
NCT06449482 · Institute of Hematology & Blood Diseases Hospital, China
2023-05-05 – 2025-03-30 · Acute Myeloid Leukemia, Adult
What this study did
NCT04435691 · M.D. Anderson Cancer Center
2020-07-28 – 2025-03-25 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT06150040 · Centre Leon Berard
2024-09-11 – 2025-02-18 · Acute Myeloid Leukemia Refractory
What this study did
NCT04485052 · Innovent Biologics (Suzhou) Co. Ltd.
2020-09-25 – 2024-12-31 · Acute Myeloid Leukemia
What this study did
NCT03932318 · Actinium Pharmaceuticals
2023-03 – 2024-09 · Acute Myeloid Leukemia, Relapsed Adult AML
What this study did
NCT04623216 · Novartis Pharmaceuticals
2021-09-14 – 2024-08-22 · Acute Myeloid Leukemia
What this study did
NCT05949762 · ZePing Zhou
2023-04-01 – 2024-04-01 · Acute Myeloid Leukemia
What this study did
NCT03825367 · Therapeutic Advances in Childhood Leukemia Consortium
2019-11-29 – 2024-03-30 · AML, Childhood
What this study did
NCT02719574 · Forma Therapeutics, Inc.
2016-04-30 – 2024-01-24 · Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
NCT04752163 · M.D. Anderson Cancer Center
2021-03-25 – 2023-11-08 · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT04629443 · Institut de Recherches Internationales Servier
2021-02-17 – 2023-08-25 · Acute Myeloid Leukaemia
What this study did
NCT03047993 · M.D. Anderson Cancer Center
2017-11-15 – 2023-03-16 · Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-2, Myelodysplastic Syndrome
What this study did
NCT01892371 · M.D. Anderson Cancer Center
2013-11-12 – 2023-02-07 · FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT05061147 · Maxinovel Pty., Ltd.
2021-09-16 – 2022-10-31 · Leukemia, Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT03390296 · M.D. Anderson Cancer Center
2017-12-27 – 2022-02-04 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03072043 · H. Lee Moffitt Cancer Center and Research Institute
2017-05-18 – 2021-12-08 · Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia
What this study did
NCT02829840 · M.D. Anderson Cancer Center
2016-09 – 2021-09 · Leukemia, FLT3-Mutated Acute Myeloid Leukemia, FLT3-Mutated High-Risk Myelodysplastic Syndrome
What this study did
NCT03588078 · Groupe Francophone des Myelodysplasies
2018-09-15 – 2021-05-15 · Myelodysplastic Syndrome With Gene Mutation, Acute Myeloid Leukemia With Gene Mutations, Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia
What this study did
NCT02265731 · AbbVie
2014-09-22 – 2021-03-12 · Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Acute Myeloid Leukemia (AML)
What this study did
NCT01926587 · Traws Pharma, Inc.
2013-08 – 2021-02-16 · Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
What this study did
NCT03701295 · National Cancer Institute (NCI)
2020-03-06 – 2021-01-12 · Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT01369368 · University of Bergen
2013-08 – 2020-10 · Acute Myeloid Leukemia
What this study did
Phase 1 (179)
Acute Myeloid Leukemia
NCT07320235 · Douglas Tremblay
2026-01-02 – 2035-06-15 · Relapsed Acute Myeloid Leukemia
What this study did
NCT07828535 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-30 – 2032-12-31 · Acute Myeloid Leukemia (AML)
What this study did
NCT06454409 · City of Hope Medical Center
2025-04-25 – 2030-09-06 · Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT07722767 · Cullinan Therapeutics Inc.
2026-10-15 – 2030-08-31 · AML (Acute Myeloid Leukemia)
What this study did
NCT07645469 · Fred Hutchinson Cancer Center
2026-12-01 – 2030-07-19 · Acute Myeloid Leukemia
What this study did
NCT05735184 · Kura Oncology, Inc.
2023-07-18 – 2030-04 · Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
What this study did
NCT03613532 · Jacqueline Garcia, MD
2018-10-24 – 2030-03-05 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
What this study did
NCT07177079 · Kittika Poonsombudlert
2026-03-18 – 2029-12-31 · Acute Myeloid Leukemia
What this study did
NCT06616636 · M.D. Anderson Cancer Center
2025-01-30 – 2029-08-27 · Myelodysplastic Syndrome, Acute Myeloid Leukemia
What this study did
NCT07439211 · Jacqueline Garcia, MD
2026-04-13 – 2029-02-01 · Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia, Refractory Leukemia
What this study did
NCT06177067 · St. Jude Children's Research Hospital
2024-04-19 – 2029-02 · Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
What this study did
NCT07094464 · Daihong Liu
2025-06-01 – 2028-12-30 · TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation
What this study did
NCT07548983 · OHSU Knight Cancer Institute
2026-04-21 – 2028-12-29 · Acute Myeloid Leukemia
What this study did
NCT06533761 · Stelexis BioSciences
2025-04-28 – 2028-09-15 · AML, Adult, MDS
What this study did
NCT04227847 · Seagen, a wholly owned subsidiary of Pfizer
2020-08-07 – 2028-07-03 · Myelodysplastic Syndrome, Acute Myeloid Leukemia
What this study did
NCT06445907 · M.D. Anderson Cancer Center
2025-02-12 – 2028-07-01 · Acute Myeloid Leukemia
What this study did
NCT05834244 · M.D. Anderson Cancer Center
2023-10-26 – 2028-06-30 · Acute Myeloid Leukemia
What this study did
NCT06357182 · OHSU Knight Cancer Institute
2024-08-22 – 2028-05-29 · Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
What this study did
NCT06634394 · Aptevo Therapeutics
2024-10-01 – 2028-03 · Acute Myeloid Leukemia (AML)
What this study did
NCT06651229 · Janssen Research & Development, LLC
2025-03-21 – 2028-02-09 · Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
What this study did
NCT03874052 · Jennifer Saultz
2019-08-16 – 2027-12-31 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
What this study did
NCT05476770 · Therapeutic Advances in Childhood Leukemia Consortium
2022-11-11 – 2027-11-11 · Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
What this study did
NCT06429449 · University of Colorado, Denver
2024-07-21 – 2027-11 · Leukemia, Myeloid Leukemia, Monocytic Leukemia
What this study did
NCT06514261 · National Cancer Institute (NCI)
2024-12-18 – 2027-09-16 · Acute Myeloid Leukemia
What this study did
NCT06372717 · Apollo Therapeutics Ltd
2024-06-04 – 2027-08 · Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia (AML), Newly Diagnosed Acute Myeloid Leukemia (AML)
What this study did
NCT07303660 · Lomond Therapeutics Holdings, Inc.
2025-11-14 – 2027-07 · Acute Myeloid Leukemia
What this study did
NCT05453903 · Janssen Research & Development, LLC
2022-10-04 – 2027-06-30 · Leukemia, Myeloid, Acute
What this study did
NCT03113643 · Dana-Farber Cancer Institute
2017-06-26 – 2027-05-31 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
What this study did
NCT04150887 · OncoVerity, Inc.
2019-12-23 – 2027-05-15 · Leukemia, Myeloid, Acute
What this study did
NCT04603001 · Eli Lilly and Company
2020-11-19 – 2027-05 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
What this study did
NCT06498973 · City of Hope Medical Center
2025-01-28 – 2027-04-25 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT04243785 · Edgewood Oncology Inc.
2020-01-06 – 2027-03 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT06763341 · City of Hope Medical Center
2025-07-30 – 2027-01-16 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03513484 · Northwestern University
2018-11-14 – 2027-01 · Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal Tandem Duplication, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT05001828 · Polaris Group
2022-04-05 – 2027-01 · Acute Myeloid Leukemia, Adult
What this study did
NCT05317403 · Medical College of Wisconsin
2023-03-31 – 2027-01 · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
What this study did
NCT06737523 · The First Affiliated Hospital of Xiamen University
2025-03-15 – 2026-12-31 · Acute Myeloid Leukemia, Relapse, Refractory AML
What this study did
NCT06550713 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2019-10-22 – 2026-12 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
What this study did
NCT05673057 · Molecular Partners AG
2022-12-29 – 2026-09-14 · Leukemia, Myeloid, Acute, Newly Diagnosed
What this study did
NCT06419634 · Bristol-Myers Squibb
2024-05-29 – 2026-08-28 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT05720988 · Jonsson Comprehensive Cancer Center
2024-08-03 – 2026-08-03 · Acute Myeloid Leukemia
What this study did
NCT05823480 · City of Hope Medical Center
2024-10-09 – 2026-02-14 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT04139434 · Newave Pharmaceutical Inc
2020-07-06 – 2025-12-19 · AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML
What this study did
NCT04964505 · Brian Jonas
2021-07-02 – 2025-10-07 · Acute Myeloid Leukemia
What this study did
NCT06326697 · Hikma Pharmaceuticals LLC
2024-05-02 – 2025-08-28 · Acute Myeloid Leukaemia
What this study did
NCT04372433 · Immune-Onc Therapeutics
2020-09-14 – 2025-01-31 · AML With Monocytic Differentiation, CMML
What this study did
NCT04553692 · IGM Biosciences, Inc.
2020-09-23 – 2025-01-20 · Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
What this study did
Phase 4 (8)
Acute Myeloid Leukemia
NCT07773909 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2022-06-01 – 2023-03-01 · Acute Myeloid Leukemia
What this study did
Myelodysplastic Syndromes
NCT06004765 · Peking Union Medical College Hospital
2023-08 – 2025-08 · Myelodysplastic Syndromes
What this study did
NCT03873311 · Shenzhen Second People's Hospital
2019-09-01 – 2023-06-01 · Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
What this study did
NCT01201811 · Celgene
2010-10-01 – 2013-05-01 · Myelodysplastic Syndromes
What this study did
NCT01011283 · Eisai Inc.
2009-11 – 2011-01 · Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT07046182 · Zhengzhou University
2023-10-21 – 2028-05-26 · Angioimmunoblastic T-cell Lymphoma (AITL)
What this study did
Early phase / not applicable (33)
Acute Myeloid Leukemia
NCT06841952 · The First Affiliated Hospital of Soochow University
2025-02-15 – 2030-12-15 · AML, Adult
What this study did
NCT07635485 · The First Affiliated Hospital of Soochow University
2026-06-01 – 2029-08-31 · Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult)
What this study did
NCT07762508 · The First Affiliated Hospital of Soochow University
2026-08 – 2029-07 · Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT)
What this study did
NCT07490288 · Institute of Hematology & Blood Diseases Hospital, China
2026-05-08 – 2029-03-01 · AML
What this study did
NCT07131059 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-11 – 2028-10-30 · AML, Adult
What this study did
NCT06265545 · Institute of Hematology & Blood Diseases Hospital, China
2024-02-22 – 2028-06-30 · AML, Refractory, Relapsed
What this study did
NCT05772273 · The First Affiliated Hospital of Soochow University
2023-03-15 – 2027-12-31 · Acute Myeloid Leukemia
What this study did
NCT06386302 · Institute of Hematology & Blood Diseases Hospital, China
2024-08-05 – 2027-12-30 · AML, Acute Myeloid Leukemia
What this study did
NCT06090786 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2024-07 – 2027-07 · AML, Adult, Minimal Residual Disease
What this study did
NCT06256627 · Henan Cancer Hospital
2023-07-11 – 2027-05-01 · Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b, Interleukin-2, Thalidomide, Venentoclax, Azacitidine
What this study did
NCT06066905 · Guangdong Provincial People's Hospital
2023-10-26 – 2026-12 · AML, Adult, Minimal Residual Disease
What this study did
NCT06572982 · Hikma Pharmaceuticals LLC
2025-04-29 – 2026-05 · Acute Myeloid Leukemia
What this study did
NCT05262465 · guomei
2020-07-01 – 2025-07-01 · Adult Acute Myeloid Leukemia
What this study did
NCT06030089 · Centre Hospitalier Universitaire de Nice
2024-02-26 – 2025-03-03 · Acute Myeloid Leukemia
What this study did
NCT05805072 · The First Affiliated Hospital of Soochow University
2023-05-01 – 2024-06-30 · Relapsed/Refractory AML
What this study did
NCT05266274 · The First Affiliated Hospital of Soochow University
2021-12-14 – 2023-12-31 · Patients With Recurrent Acute Myelogenous Leukemia After Transplantation
What this study did
NCT05471700 · Zhujiang Hospital
2022-09-01 – 2023-04-04 · Leukemia, Myeloid, Acute
What this study did
NCT05053425 · LanZhou University
2021-10-20 – 2023-03-18 · Acute Myeloid Leukemia
What this study did
Myelodysplastic Syndromes
NCT06886425 · Assistance Publique Hopitaux De Marseille
2021-06-14 – 2028-06-14 · Myelodysplastic Syndromes (MDS), Leukemia Acute Myeloid - AML
What this study did
NCT06279338 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-03-01 – 2026-01-31 · Myelodysplastic Syndromes
What this study did
NCT03217903 · Central Hospital, Nancy, France
2017-10-12 – 2022-01-01 · High-risk Myelodysplastic Syndromes With Excess Blasts
What this study did
NCT02489929 · Assistance Publique Hopitaux De Marseille
2015-08 – 2019-03 · Myeloid Leukemia, Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT07542912 · Sun Yat-sen University
2026-06-01 – 2029-06-01 · Complete Remission Rate, CRR, Progression Free Survival, Overall Survival, Adverse Event, Duration of Response
What this study did
NCT04505995 · Air Force Military Medical University, China
2020-01-01 – 2025-01-01 · JMML
What this study did
NCT05772728 · The First Affiliated Hospital with Nanjing Medical University
2023-04 – 2024-12 · T Cell Lymphoma
What this study did
NCT05797948 · The First Affiliated Hospital of Soochow University
2022-07-01 – 2024-06-30 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
What this study did
NCT05058755 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2021-09-17 – 2023-12-30 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
What this study did
NCT04078399 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2019-08-28 – 2022-08-28 · HSCT, Efficacy and Safety
What this study did
NCT01050790 · Virginia Commonwealth University
2010-01 – 2016-09 · Multiple Myeloma
What this study did
NCT00660400 · H. Lee Moffitt Cancer Center and Research Institute
2008-03 – 2014-06 · Leukemia
What this study did
NCT01209520 · University of Miami
2009-07 – 2013-12 · Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
What this study did
NCT01292083 · University of Southern California
2011-01 – 2013-03 · Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
What this study did
Used as active comparator (14)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Acute Myeloid Leukemia
NCT05586074 · Sunshine Lake Pharma Co., Ltd.
2023-03-03 – 2028-05-30 · Leukemia, Acute Myeloid (AML)
What this study did
NCT04229979 · Sellas Life Sciences Group
2021-02-08 – 2026-12 · Acute Myeloid Leukemia
What this study did
NCT06073730 · The Second Affiliated Hospital of Kunming Medical University
2023-11-01 – 2026-04-30 · Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia, Venetoclax, Decitabine
What this study did
NCT03926624 · Delta-Fly Pharma, Inc.
2019-11-22 – 2026-01-07 · Leukemia, Myeloid, Acute
What this study did
NCT02421939 · Astellas Pharma Global Development, Inc.
2015-10-20 – 2025-02-25 · Leukemia, Acute Myeloid (AML)
What this study did
NCT02752035 · Astellas Pharma Global Development, Inc.
2016-08-01 – 2024-12-18 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
What this study did
Myelodysplastic Syndromes
NCT07735117 · Ruijin Hospital
2026-07-30 – 2029-07-31 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
What this study did
Phase 2 (4)
Acute Myeloid Leukemia
NCT07710534 · Virginia Commonwealth University
2026-09-16 – 2033-12-31 · Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
What this study did
NCT06770257 · Institute of Hematology & Blood Diseases Hospital, China
2025-12-10 – 2027-06-10 · Leukemia, Myeloid, Acute
What this study did
Myelodysplastic Syndromes
Other / comorbidity
NCT01404741 · Universitätsklinikum Hamburg-Eppendorf
2011-07 – 2021-07 · Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
What this study did
Phase 1 (1)
Acute Myeloid Leukemia
NCT02954653 · Pfizer
2016-11-28 – 2017-12-05 · Acute Myeloid Leukemia
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (1)
Acute Myeloid Leukemia
NCT05654194 · The First Affiliated Hospital of Soochow University
2022-10-31 – 2026-02-28 · Acute Myeloid Leukemia
What this study did
Appears in other studies (34)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (15)
Acute Myeloid Leukemia
NCT07539818 · Institute of Hematology & Blood Diseases Hospital, China
2026-05-15 – 2031-04-01 · AML
What this study did
NCT06852222 · Janssen Research & Development, LLC
2025-06-04 – 2029-08-15 · Leukemia, Myeloid, Acute
What this study did
NCT06389292 · Ascentage Pharma Group Inc.
2024-06-11 – 2029-03-26 · Acute Myeloid Leukemia
What this study did
NCT04090736 · PETHEMA Foundation
2019-09-24 – 2026-07-30 · Leukemia, Myeloid, Acute
What this study did
NCT03173248 · Institut de Recherches Internationales Servier
2017-06-26 – 2026-06-30 · Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
What this study did
NCT05079230 · Gilead Sciences
2022-07-07 – 2024-04-11 · Acute Myeloid Leukemia
What this study did
NCT03151408 · Helsinn Healthcare SA
2017-06-23 – 2020-08-20 · Acute Myeloid Leukemia
What this study did
NCT02785900 · Seagen Inc.
2016-05 – 2017-10-03 · Acute Myeloid Leukemia
What this study did
Myelodysplastic Syndromes
NCT04797780 · Syros Pharmaceuticals
2021-02-08 – 2024-11-13 · Myelodysplastic Syndromes
What this study did
NCT04313881 · Gilead Sciences
2020-09-09 – 2023-09-13 · Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT06641414 · Ascentage Pharma Group Inc.
2025-01-22 – 2029-12 · Higher-risk Myelodysplastic Syndrome
What this study did
NCT06647862 · ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
2024-11-11 – 2029-10-24 · Chronic Myelomonocytic Leukemia
What this study did
NCT06927232 · Peking Union Medical College Hospital
2025-04-24 – 2026-01-31 · Higher-risk Myelodysplastic Syndrome
What this study did
Phase 2/3 (1)
Phase 2 (14)
Acute Myeloid Leukemia
NCT06084819 · Chinese PLA General Hospital
2023-08-01 – 2030-01-31 · Relapsed/Refractory Acute Myeloid Leukemia
What this study did
NCT06741722 · Beijing 302 Hospital
2024-10-31 – 2027-12-31 · AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT07651475 · Liping Dou
2026-07-30 – 2027-03-31 · R/R AML
What this study did
NCT05603884 · The First Affiliated Hospital of Xiamen University
2022-12-01 – 2026-12-31 · Leukemia, Myeloid, Acute, AML Stage, Adult
What this study did
NCT06928376 · Chinese PLA General Hospital
2024-04-18 – 2026-09-01 · Acute Myeloid Leukemia, First Line Therapy
What this study did
NCT06068621 · Chinese PLA General Hospital
2023-03-01 – 2025-08-31 · Acute Myeloid Leukemia
What this study did
NCT03745352 · National Cancer Institute (NCI)
2019-05-20 – 2021-08-19 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
Myelodysplastic Syndromes
NCT07238686 · Beijing 302 Hospital
2025-06-20 – 2031-06 · Myelodysplastic Syndromes
What this study did
NCT07672769 · Faron Pharmaceuticals Ltd
2026-11 – 2030-12 · Higher Risk Myelodysplastic Syndromes
What this study did
NCT06196203 · Akeso
2024-02-07 – 2026-06 · Higher-risk Myelodysplastic Syndromes
What this study did
NCT02610777 · Millennium Pharmaceuticals, Inc.
2016-04-14 – 2021-07-23 · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
What this study did
Other / comorbidity
NCT06664970 · Peking Union Medical College Hospital
2024-11-06 – 2026-09-30 · MDS
What this study did
NCT01873703 · Helsinn Healthcare SA
2013-06 – 2016-11 · Myelodysplastic Syndrome
What this study did
Phase 1/2 (3)
Acute Myeloid Leukemia
NCT06746519 · Chen Suning
2024-12-25 – 2027-06-30 · Acute Myeloid Leukemia
What this study did
NCT06387420 · Akeso
2024-04-29 – 2027-04 · ACUTE MYELOID LEUKEMIA; AML
What this study did
Other / comorbidity
NCT02706899 · Seagen Inc.
2016-02 – 2017-11-06 · Myelodysplastic Syndrome
What this study did
Early phase / not applicable (1)
Acute Myeloid Leukemia
NCT05042531 · LanZhou University
2021-11-13 – 2023-12-15 · Acute Myeloid Leukemia
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Azacitidine: this drugPhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Decitabine / Tetrahydrouridine (NDec)
Phase 2(overall)
Small moleculeDNMT1 (DNA methyltransferase 1)
not yet graded(overall)
No reviewed efficacy summary in this indication
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 69 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(202 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Azacitidine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (27)
November 2026 (1)
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11 · NCT03850574 · CT.gov ↗
What to watch
December 2026 (26)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT05788679 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT05955261 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06066905 · CT.gov ↗
What to watch
Phase 2Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06190067 · CT.gov ↗
What to watch
Phase 1Cerebral Palsy, ContractureEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06377085 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06429449 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06783790 · CT.gov ↗
What to watch
Phase 2NK/T Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07000617 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07303660 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, RecruitingRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT05376111 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06220162 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06635681 · CT.gov ↗
What to watch
Phase 1/2CML,Blast PhaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06757855 · CT.gov ↗
What to watch
Phase 2Safety, Antitumor Activity, PK ProfileActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-01 · NCT06858618 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT04588922 · CT.gov ↗
What to watch
Phase 2Peripheral T Cell Lymphoma, Epigenetic RepressionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT05958719 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT06451861 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT00392353 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT04128501 · CT.gov ↗
What to watch
Phase 2Myeloproliferative NeoplasmRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05074355 · CT.gov ↗
What to watch
Phase 1/2T Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05230680 · CT.gov ↗
What to watch
Phase 2Hodgkin's LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05355051 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05584761 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06345365 · CT.gov ↗
What to watch
Phase 1Myelodysplastic SyndromesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06502145 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT07486479 · CT.gov ↗
What to watch
2027 (84)
January 2027 (10)
Phase 1Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT05001828 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT05317403 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT06177067 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT06384261 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT06773208 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT04801797 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT06754540 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT06886425 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-16 · NCT06763341 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-31 · NCT03862157 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1/2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02 · NCT04086264 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02 · NCT05183035 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-28 · NCT03383575 · CT.gov ↗
What to watch
March 2027 (5)
Phase 1/2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03 · NCT05428969 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-08 · NCT06357182 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT05554406 · CT.gov ↗
What to watch
Phase 1Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT07388563 · CT.gov ↗
What to watch
April 2027 (3)
Phase 2Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T/Myeloid, NosRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT07012447 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-25 · NCT06498973 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-30 · NCT03586609 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05 · NCT04891068 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-15 · NCT04150887 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT07548710 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT06656494 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT04988555 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT06429098 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT07094464 · CT.gov ↗
What to watch
July 2027 (7)
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT06090786 · CT.gov ↗
What to watch
Phase 1/2Chronic Myelomonocytic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT06159491 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT06372717 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-01 · NCT05772273 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-01 · NCT06445907 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-04 · NCT04227847 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-30 · NCT03843528 · CT.gov ↗
What to watch
August 2027 (4)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT06532552 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-05 · NCT06651229 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-27 · NCT06616636 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-30 · NCT07132684 · CT.gov ↗
What to watch
September 2027 (11)
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT07761533 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07743112 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07813390 · CT.gov ↗
What to watch
Phase 1Chronic Myeloid Leukemia, MyelofibrosesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-04 · NCT03326310 · CT.gov ↗
What to watch
Phase 1/2Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-11 · NCT04734990 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-20 · NCT03683433 · CT.gov ↗
What to watch
Phase 2Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic SyndromeActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT02530463 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT03471260 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT05401097 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT07514936 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT07722767 · CT.gov ↗
What to watch
October 2027 (10)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT06511882 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT06634394 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07163793 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07486726 · CT.gov ↗
What to watch
Early phase / not applicableMyeloid TumorsNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-01 · NCT07632170 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-11 · NCT06504459 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-15 · NCT05907057 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, RelapseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-30 · NCT06686108 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-31 · NCT06497062 · CT.gov ↗
What to watch
Phase 1/2Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-31 · NCT06523556 · CT.gov ↗
What to watch
November 2027 (3)
Phase 4Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11 · NCT07044687 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-01 · NCT04256317 · CT.gov ↗
What to watch
Phase 3Myelodysplastic SyndromesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-01 · NCT06465953 · CT.gov ↗
What to watch
December 2027 (21)
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT04581512 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT06470841 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT07255872 · CT.gov ↗
What to watch
Phase 3Peripheral T-cell Lymphoma Targeted TherapyEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT05678933 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT06548230 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT06744556 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT07304011 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-15 · NCT06533761 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT06386302 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT03874052 · CT.gov ↗
What to watch
Phase 1/2Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT04493138 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05270200 · CT.gov ↗
What to watch
Phase 2Myelodysplastic SyndromesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05365035 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05554393 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05641259 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07548983 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed Mixed Phenotype Acute LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07573670 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07748455 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07828535 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07862517 · CT.gov ↗
What to watch
Phase 1/2Myelodysplastic SyndromesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07885397 · CT.gov ↗
What to watch
2028 (51)
January 2028 (5)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT07392242 · CT.gov ↗
What to watch
Phase 1/2Peripheral T-cell Lymphoma (PTCL)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT07706959 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-01 · NCT06778902 · CT.gov ↗
What to watch
Phase 2Peripheral T Cells Lymphoma (PTCL)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-15 · NCT07372352 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-30 · NCT06265545 · CT.gov ↗
What to watch
February 2028 (7)
Phase 2/3Peripheral T Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07389616 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07407660 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07439211 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-09 · NCT06456463 · CT.gov ↗
What to watch
Phase 2Myelodysplastic SyndromesActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-14 · NCT05201066 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-20 · NCT03850418 · CT.gov ↗
What to watch
Phase 1Solid Tumor, Locally Advanced Solid Tumor, Metastatic TumorRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-28 · NCT07404332 · CT.gov ↗
What to watch
March 2028 (4)
Phase 1Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant …Enrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT06896110 · CT.gov ↗
What to watch
Phase 1Myelodysplastic SyndromesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-05 · NCT07071155 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT07469046 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT07507825 · CT.gov ↗
What to watch
April 2028 (3)
Phase 1/2Peripheral T Cells Lymphoma (PTCL), Follicular Helper T-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04 · NCT07018752 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-01 · NCT07514832 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-30 · NCT07779031 · CT.gov ↗
What to watch
May 2028 (3)
Early phase / not applicableAcute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-10 · NCT07131059 · CT.gov ↗
What to watch
Phase 4Angioimmunoblastic T-cell Lymphoma (AITL)Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-26 · NCT07046182 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-31 · NCT07664839 · CT.gov ↗
What to watch
June 2028 (6)
Phase 2/3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT05404906 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT06668558 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT07471841 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-01 · NCT07642453 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of Head and NeckRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-30 · NCT05317000 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-30 · NCT05834244 · CT.gov ↗
What to watch
July 2028 (5)
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07 · NCT07605949 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-02 · NCT05292664 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-31 · NCT05520567 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-31 · NCT06664879 · CT.gov ↗
What to watch
Phase 2Peripheral T-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-31 · NCT07746245 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-31 · NCT04771130 · CT.gov ↗
What to watch
September 2028 (6)
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09 · NCT04501120 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT04140487 · CT.gov ↗
What to watch
Phase 1/2Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell LymphomasRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT06176027 · CT.gov ↗
What to watch
Phase 2Adult T-cell Leukemia/LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07159620 · CT.gov ↗
What to watch
Phase 1Myeloproliferative NeoplasmNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07679334 · CT.gov ↗
What to watch
Phase 2/3Myelodysplastic SyndromesNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07932873 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2/3Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-01 · NCT07425808 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-01 · NCT06557421 · CT.gov ↗
What to watch
December 2028 (9)
Phase 1/2Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL SyndromeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT05849662 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT06014489 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT07060001 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-11 · NCT07646821 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-15 · NCT06841952 · CT.gov ↗
What to watch
Phase 1Refractory Acute Leukemia, Pediatric RelapsedRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT06397027 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07148180 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative NeoplasmRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07148947 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07177079 · CT.gov ↗
What to watch
2029 (21)
February 2029 (1)
Phase 3Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02-01 · NCT07407140 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-03-31 · NCT06782542 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-04 · NCT06696183 · CT.gov ↗
What to watch
May 2029 (3)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-05-15 · NCT05564390 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-05-15 · NCT06317649 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-05-31 · NCT07635485 · CT.gov ↗
What to watch
June 2029 (2)
Early phase / not applicableComplete Remission Rate, CRR, Progression Free Survival, Overall Survival, Adverse Event, Duration of ResponseNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-06-01 · NCT07542912 · CT.gov ↗
What to watch
Phase 2Myelodysplastic SyndromesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-06-30 · NCT07047183 · CT.gov ↗
What to watch
July 2029 (1)
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-07 · NCT07762508 · CT.gov ↗
What to watch
September 2029 (2)
Phase 1/2Myelodysplastic SyndromesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-09-01 · NCT06471946 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-09-30 · NCT07754799 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-10-01 · NCT07755202 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-11-24 · NCT07691450 · CT.gov ↗
What to watch
December 2029 (8)
Phase 2/3Acute Myeloid LeukemiaEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2029-12 · NCT07651163 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2029-12 · NCT07651176 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12 · NCT07925190 · CT.gov ↗
What to watch
Phase 2LALNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-01 · NCT07522801 · CT.gov ↗
What to watch
Phase 1/2PTCL, RefractoryNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-12 · NCT07493330 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-12 · NCT07508982 · CT.gov ↗
What to watch
Phase 2NK T-Cell LymphomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-30 · NCT07276698 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT07949370 · CT.gov ↗
What to watch
2030 (16)
January 2030 (1)
Phase 1Peripheral T-Cell Lymphoma RefractoryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-01-01 · NCT07598578 · CT.gov ↗
What to watch
April 2030 (3)
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-04 · NCT05735184 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-04 · NCT07478991 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-04-30 · NCT07770698 · CT.gov ↗
What to watch
June 2030 (3)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06 · NCT07078591 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06-01 · NCT07672262 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06-17 · NCT07320235 · CT.gov ↗
What to watch
July 2030 (2)
Phase 1Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-07-19 · NCT07645469 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-07-21 · NCT05442216 · CT.gov ↗
What to watch
August 2030 (3)
Phase 3Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-10 · NCT07686965 · CT.gov ↗
What to watch
Phase 2Cerebral PalsyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-31 · NCT07433023 · CT.gov ↗
What to watch
Phase 2Cerebral PalsyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-31 · NCT07434492 · CT.gov ↗
What to watch
September 2030 (3)
Phase 2Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09 · NCT05904106 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09 · NCT06598384 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09 · NCT07082452 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-12-31 · NCT05554419 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-11 · NCT07007312 · CT.gov ↗
What to watch
2032 (2)
June 2032 (1)
Phase 2/3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-06 · NCT07581002 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2/3Acute Myeloid LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-12 · NCT03013998 · CT.gov ↗
What to watch

See the full readout calendar ↗